NEW YORK (GenomeWeb News) – Leerink Swann today upgraded shares of Fluidigm, noting a potentially multi-billion market opportunity for single-cell gene expression tools and the recent acquisition of DVS Sciences as drivers.
NEW YORK (GenomeWeb News) – Leerink Swann today downgraded Fluidigm to Market Perform, saying the company "could take a breather in the near term" after a 30 percent spike in its stock since the start of the year.
Investment bank Leerink Swann anticipates a four-percent decline in Illumina's core microarray business this year due to increased adoption of next-generation sequencing, a reduction in available federal funding, and competition from Affymetrix.
NEW YORK (GenomeWeb News) – Leerink Swann downgraded Waters today to Market Perform, saying the company could be challenged by the macroeconomic environment and softer end-markets, as well as increasing competition for its products and services.
NEW YORK (GenomeWeb News) – A Leerink Swann survey of diagnostic laboratories in Europe found that molecular-based testing continues to find traction with continued penetration strongest in methicillin-resistant Staphylococcus aureus testing and human papillomavirus testing.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investment bank Leerink Swann today upgraded Life Technologies to Outperform, noting the potential growth of the company's next-generation sequencing business.
The investment firm lowered its estimates from levels predicted last week to reflect lost consumables sales on its older next-gen sequencing platforms and softer microarray consumables sales sequentially.
Spending on life science tools rose 13 percent in the fourth quarter of 2010, suggesting that the "effects of the continuing resolution on NIH budgets have not dampened the underlying demand for tools in the US academic sector."